HIM
AXSM icon

Hillsdale Investment Management’s Axsome Therapeutics AXSM Stock Holding History

Hillsdale Investment Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5M Buy
55,000
+1,637
+3% +$355K 0.31% 64
2026
Q1 		$9.02M Buy
+53,363
New +$9.22M 0.25% 71

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Hillsdale Investment Management's AXSM Position: Q2 2026 in Review

Hillsdale Investment Management increased its Axsome Therapeutics (AXSM) stake by 3.1% in Q2 2026, buying an estimated $355K and bringing the position to 55,000 shares worth $13.5M. The position accounts for 0.31% of the portfolio, ranked #64.

Hillsdale Investment Management first reported a position in AXSM in Q1 2026 and has held it in 2 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Hillsdale Investment Management held 55,000 shares of Axsome Therapeutics worth $13.5M as of Q2 2026.
  • Hillsdale Investment Management bought 1,637 Axsome Therapeutics shares in Q2 2026, an estimated $355K.
  • Axsome Therapeutics made up 0.31% of Hillsdale Investment Management's portfolio in Q2 2026, its #64 holding.
  • Hillsdale Investment Management first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.